NCT02170571View on ClinicalTrials.gov

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

December 31, 2005

Conditions
Hepatic Insufficiency
Interventions
DRUG

Dabigatran etexilate

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY